Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, open-label, non-randomized cohort study evaluating the efficacy and safety of a pediatric-inspired chemotherapy regimen (IH-2014 based) combined with venetoclax and immunotherapy in adult patients with newly diagnosed Ph-negative Acute Lymphoblastic Leukemia (ALL). Patients aged ≥14years,≤60 years will be enrolled. Treatment includes induction, consolidation, early intensification, delayed intensification, and maintenance phases. The use and number of cycles of immunotherapy will be based on patient preference. The primary endpoint is Event-Free Survival (EFS) and MRD-negative CR rates after induction therapy(by flow cytometry and NGS). Secondary endpoints include Complete Remission (CR) rate, MRD-negative CR rates at 12 weeks (by flow cytometry and NGS), Overall Survival (OS), Relapse-Free Survival (RFS), and cumulative relapse rate.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Nowo rozpoznana białaczka ALL, dotąd nieleczona (poza lekami przygotowawczymi)
- •Wiek od 14 do 60 lat
- •Dobry ogólny stan zdrowia (skala ECOG 0-2)
- •Prawidłowa funkcja wątroby, nerek i serca
- •Stosowanie antykoncepcji dla osób w wieku rozrodczym
- •Chęć i zdolność do udzielenia świadomej zgody
✗ Disqualifies
- •Białaczka typu Burkitt
- •Ciąża lub karmienie piersią
- •Ciężka, niekontrolowana aktywna infekcja
- •Historia zapalenia trzustki
- •Niekontrolowana cukrzyca
- •Krwawienie z przewodu pokarmowego w ostatnich 6 miesiącach
- •Zakrzepy naczyniowe w ostatnich 6 miesiącach
- •Potwierdzony wirus HIV
Simplified criteria — AI translation
Trial details
- Minimum age
- 14 Years
- Maximum age
- 60 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Blood Diseases Hospital
Tianjin, China
Trial contact
Hui Wei, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.